Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Good
|
New words:
abandoned, aforementioned, Alfimeprase, aliquoting, arm, assumption, attaining, attention, beta, BioOncology, BioPharma, bioreactor, bought, boyer, branded, Cabilly, CAMPATH, CAP, certiorari, chargeback, charitable, choose, CHOP, CIP, Citigroup, Clark, clearing, CMS, comment, comparison, compelling, compendium, contest, contrast, correspondingly, count, coupon, CRC, cyclophosphamide, debra, dedicate, destroyed, DI, diligently, discharge, divert, donated, double, doxorubicin, DSMB, duly, education, emerging, empirical, employment, Escrow, ESP, excellent, exhibit, exploit, extinguish, extinguished, flat, flexibility, furnished, gastrointestinal, gefitinib, gestational, Goldman, Google, grand, heading, herbert, hereof, herewith, holder, Humatrope, Humira, Huningue, hypersensitivity, hypertonic, Ian, inapplicable, incorrect, Indenture, induction, inexpensive, Instruction, intravitreal, ISS, Johnson, Kingdom, lapatinib, lawfully, leasehold, lengthier, leukotriene, liable, lot, Maine, malate, myeloma, neovascular, Nexavar, nontransferable, notification, Nuvelo, occupancy, Oceanside, omitted, owner, panitumumab, path, PDL, peer, Pfizer, Pharmacopeia, placement, postretirement, power, Prader, procedure, proforma, promulgated, qualification, qui, ratifying, ratio, RCC, recommendation, redacted, reed, reexamination, rejecting, Remicade, reorder, resale, resubstitution, retaliatory, retinal, Rocheexercised, rolling, routine, Saizen, saline, seal, SGA, shell, shortly, signature, smaller, sorafenib, statute, stead, steadily, step, sterility, stromal, submission, sunitinib, suspended, Sutent, tam, Teva, thereunto, therewith, Toll, Treasury, true, trustee, unchanged, undersigned, understood, unplanned, unresectable, unsealed, uptake, USP, valuable, VELCADE, Version, virtue, vulnerability, wait, waiting, wholly, Willi, writ, XELOX, ZactimaTM, Zyflo
Removed:
Academy, accelerated, accretion, acid, Advancement, aimed, alternatively, America, American, amino, ancillary, antidilutive, began, Biochemistry, Bulletin, capability, classification, commonly, community, compensated, conflict, consecutive, constitute, construing, contingent, convenience, cooperative, customized, defendant, dissemination, editorial, ending, endocrine, enhanced, entry, etanercept, existence, failed, Fellow, Finally, financed, fluctuate, foregoing, forma, formed, handling, idle, idling, impacted, improved, improving, inadequacy, indemnification, inflammatory, infringe, initiating, instituted, insufficient, invalidity, jointly, Jr, Lavigne, lessee, loan, low, MabThera, Markman, matured, Medicinal, medicine, methionine, Microbiology, modest, narrower, North, Northeast, panel, paper, park, Pennwalt, performed, pivotal, plaintiff, positively, Postdoctoral, predecessor, Princeton, pro, ProLease, Protecting, published, quantifiable, quantitative, randomized, rationale, recording, remote, representative, ruled, Sacramento, shareholder, shipping, showed, shown, size, slightly, slower, Society, sooner, SPC, sponsored, stay, staying, stipulation, strength, structure, subsumed, suit, supplement, supported, survival, targeted, Taxol, technical, technologically, temporary, treated, treating, trend, unanimously, unrelated, vascular
Filing tables
Filing exhibits
- 10-K Annual report
- 3.5 Bylaws
- 10.23 First Amendment to Transition Agreement Between Genentech, Inc. and Myrtle S. Potter Dated December 29, 2005
- 10.28 First Amendment to the Manufacturing and Supply Agreement Between Genentech, Inc. and Lonza Biologics, Inc. Dated March 14, 2005
- 10.30 First Amendment to the Toll Manufacturing Agreement by and Between Wyeth, Acting Through Its Wyeth Pharmaceuticals Division, and Genentech, Inc. Dated December 8, 2004
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification of Chief Executive Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended
- 31.2 Certification of Chief Financial Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended
- 32.1 Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
Related press release
Genentech similar filings
Filing view
External links
EXHIBIT 32.1
CERTIFICATIONS OF
CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Arthur D. Levinson, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Genentech, Inc. on Form 10-K for the year ended December 31, 2005 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report of Genentech, Inc. on Form 10-K fairly presents in all material respects the financial condition and results of operations of Genentech, Inc.
By: | /s/ ARTHUR D. LEVINSON | ||
Name: Title: Date: | Arthur D. Levinson, Ph.D. Chief Executive Officer February 17, 2006 |
I, David A. Ebersman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Genentech, Inc. on Form 10-K for the year ended December 31, 2005 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report of Genentech, Inc. on Form 10-K fairly presents in all material respects the financial condition and results of operations of Genentech, Inc.
By: | /s/ DAVID A. EBERSMAN | ||
Name: Title: Date: | David A. Ebersman Executive Vice President and Chief Financial Officer February 17, 2006 |